:...Investigators from Princess Margaret Cancer Centre in Toronto and the University of California, Los Angeles, have submitted an Investigational New Drug (IND) application for CFI-400945, a novel drug candidate targeting the enzyme PLK4, which plays a crucial role in cell division.
The news was announced at a press briefing by Tak Mak, MD, OC, PhD, DSc (Hon), FRSC, FRS, Director of The Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, and Dennis J. Slamon, MD, PhD, Director of Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center.
In lab studies, the agent has been shown to effectively inhibit the growth of human breast and ovarian cancers, as well as colorectal, glioblastoma, lung, melanoma, pancreatic, and prostate cancers.
The new drug will enter clinical trials in the months ahead, upon completion of the FDA’s review of the IND application..".
Parry I agree but I felt the news would come out mid last week. I would look for the news to be the start of a phase three trial. If in fact that is the news then they have an excellent drug. The company would not move into a phase three trial without positive knowledge of their drug. Just me feeling we shall see. As always as Jimmy Buffett once wrote in a song, ONLY TIME WILL TELL. I think we are getting very close great management team and Dr. Tak Mak is the MAN